8:15 am Virtual Coffee Room Opens

8:45 am Chair’s Opening Remarks

• Lawrence Lamb EVP & CSO, In8Bbio

Targeting Solid Tumors with Combination Approaches

9:00 am Harnessing the Next Wave of Immune Checkpoints to Enhance Cell Therapy in Solid Tumors

• Marc Van Dijk CTO, AgenTus Therapeutics

9:30 am Leveraging Immune-Adjuvants to Enhance T Cell Therapy in Solid Tumors

10:00 am Understanding the Solid Tumor Microenvironment to Devise Multi-Targeting Strategies

• Jakob Dupont EVP, Head of Global Research & Development, Atara Biotherapeutics

10:30 am Morning Refreshments & Speed Networking

Harnessing Natural Immune Biology to Inform Multi-Targeted Strategies

11:00 am Targeting the Solid Tumor Microenvironment with Synergistic Therapy to Enhance T Cell Infiltration and Survival

• Francesco Marincola CSO, Refuge Biotech

11:30 am Leveraging TILs to Engage Solid Tumors as a Natural Multi-Targeted Approach

• Madan Jagasia SVP Medical Affairs, Iovance Biotherapeutics Inc.

11:50 am CRISPR/Cas9 Engineered TIL for Supercharged T Cell Function

• Micah Benson VP, Head of Immunobiology, KSQ Therapeutics

12:10 pm Expert Panel Q&A: Challenges, Strengths and Next Steps in Advancing TIL Therapies

• Madan Jagasia SVP Medical Affairs, Iovance Biotherapeutics Inc.
• Micah Benson VP, Head of Immunobiology, KSQ Therapeutics

12:30 pm Lunch & Networking

Leveraging Logic to Enhance Tumor-Specificity

1:30 pm Developing Engineering Solutions to Promote Tumor-Targeting, and Function in the Tumor Microenvironment

• Melita Irving Group Leader, Ludwig Institute for Cancer Research Lausanne

2:00 pm Developing Co-Stimulatory Domains to Create Robust, Target Cell-Specific Activation

• Marco Ruella Assistant Professor of Medicine, University of Pennsylvania

2:30 pm Advancing Target Identification to Identify Novel, Clinically Relevant Targets Quickly

• Hanspeter Gerber CSO, 3T Biosciences

3:00 pm Afternoon Poster Session & Networking

Tuned Tumor Killing with Synergistic Therapy

3:30 pm Targeting Multiple Antigens with Antibody-Redirected CARs Sequentially vs. Simultaneously

• Travis Young VP Biologics, Calibr at Scripps Research

4:00 pm Personalized Adoptive TCR-T Cell Therapies Targeting Neoantigens for the Treatment of Solid Tumors

• Barbara Sennino Director, Tumor Immunology, PACT Pharma

4:00 pm Employing Viral Combinations to Make Solid Tumors Vulnerable to CAR-T Therapy

• Saul Priceman Principal Investigator, City of Hope

4:30 pm Suppressing the Tumor Microenvironment with Combination Therapy to Enhance Anti-Tumor Efficacy in Solid Tumor Indications

5:00 pm Chair’s Closing Remarks

• Lawrence Lamb EVP & CSO, In8Bbio

5:15 pm Close of Summit